Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]

• Main Authors: Shinta Oktya Wardhani, -, Jonny Karunia Fajar, -, Laksmi Wulandari, -, Gatot Soegiarto, -, Yeni Purnamasari, -, Anisa Asmiragani, -, Helnida Anggun Maliga, -, Muhammad Ilmawan, -, Gloriana Seran, -, Dheka Sapti Iskandar, -, Conchita Emiliana Ndapa, -, Viviana Hamat, -, Rafika Ajeng Wahyuni, -, Linda Oktaviana Suci Cyntia, -, Feronika Maryanti Maarang, -, Yosef Andrian Beo, -, Olivera Agnes Adar, -, Iraky Mardya Rakhmadhan, -, Emilia Tiara Shantikaratri, -, Ayu Sekarani Damana Putri, -, Rizqa Wahdini, -, Endang Pati Broto, -, Agnes Wanda Suwanto, -, Fredo Tamara, -, Aditya Indra Mahendra, -, Eden Suryoiman Winoto, -, Pratista Adi Krisna, -, Harapan, -
• Format: Article PeerReviewed
• Language: English; English; English; English; English
• Published: Francis & Taylor 2021
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: https://repository.unair.ac.id/118329/1/Karil%20Artikel%2018.pdf; https://repository.unair.ac.id/118329/2/2.%20TURNITIN_Artikel%2018.pdf; https://repository.unair.ac.id/118329/3/1.%20Full%20Text_Artikel%2018.pdf; https://repository.unair.ac.id/118329/7/1.Karil_18.pdf; https://repository.unair.ac.id/118329/8/4.%20Korespondensi_18.pdf; https://repository.unair.ac.id/118329/; https://f1000research.com/articles/10-64/v3; https://doi.org/10.12688/f1000research.36396.3
• Institution: Universitas Airlangga

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non – RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.